During the corresponding time, Inari Medical Inc recorded a revenue increase by 21.17 % year on year, sequentially revenue grew by 5.33 %. While revenue at the Inari Medical Inc 's corporate clients
Inari Medical Inc's Comment on Sales, Marketing and Customers
The company provides services to interventional and non-interventional physicians, nursing staff, and other hospital personnel involved in medical procedures. Its medical affairs team, led by Thomas Tu, M.D., offers training and educational programs through the Clot Warrior Academy and other events. The company focuses on clinical research for treatments of venous thromboembolism (VTE), pulmonary embolism (PE), deep vein thrombosis (DVT), and chronic limb-threatening ischemia (CLTI). It conducts multiple large prospective studies and randomized controlled trials, including FLASH, FLAME, PEERLESS, PEERLESS II, CLOUT, DEFIANCE, PROMISE I, and PROMISE II. These studies enroll patients with PE, DVT, and CLTI across numerous centers and sites.
Inari Medical Inc., a leading medical technology company focused on developing groundbreaking devices for the treatment of vascular diseases, has been hit with a class action securities lawsuit. The legal action was brought about by Levi and Korsinsky, LLP, a renowned New York-based law firm specializing in securities litigation. Investors in Inari Medical (NASDAQ: NARI) have been notified of this development, which stems from alleged violations of federal securities laws by the company.During the period under review, Inari Medical Inc. experienced substantial revenue growth. Reports indicate that the company recorded an impressive year-on-year increase of 30.86%, showcasing its ability to capture a larger m...
Inari Medical Faces Class Action Amid Impressive Revenue Performance May 28, 2024 New York Inari Medical, Inc. (NASDAQ: NARI) is facing a class action lawsuit, filed by Pomerantz LLP, which has recently garnered significant attention within the financial and medical communities. The law firm announced the filing and is actively encouraging affected shareholders to reach out for more details, offering multiple contact methods including email (newaction@pomlaw.com) and a toll-free number (888.4-POMLAW) with extension 7980.The lawsuit has been filed amid a period of considerable financial growth for Inari Medical. The company recorded a remarkable 30.86% year-on-year increase in revenue. Additionally, Ina...
Inari Medical Announces Impressive Results from ClotTriever CLOUT Registry; Shows Significantly Lower Rates of Post Thrombotic Syndrome than Historical Deep Vein Thrombosis TrialsInari Medical, a global leader in medical technology, recently announced the interim two-year results from its ClotTriever CLOUT Registry. The results revealed that the rates of Post Thrombotic Syndrome (PTS) observed at two years were not only excellent but also significantly lower when compared to rates reported in historical Deep Vein Thrombosis (DVT) trials.PTS is a potentially debilitating condition that occurs in patients who have previously experienced DVT. It is characterized by the development of chronic leg pain, swelling,...
Inari Medical Inc’s Comment on Sales, Marketing and Customers
The company provides services to interventional and non-interventional physicians, nursing staff, and other hospital personnel involved in medical procedures. Its medical affairs team, led by Thomas Tu, M.D., offers training and educational programs through the Clot Warrior Academy and other events. The company focuses on clinical research for treatments of venous thromboembolism (VTE), pulmonary embolism (PE), deep vein thrombosis (DVT), and chronic limb-threatening ischemia (CLTI). It conducts multiple large prospective studies and randomized controlled trials, including FLASH, FLAME, PEERLESS, PEERLESS II, CLOUT, DEFIANCE, PROMISE I, and PROMISE II. These studies enroll patients with PE, DVT, and CLTI across numerous centers and sites.
Sources:
Inari Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Inari Medical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Inari Medical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
92.99 %